NeuroScientific Biopharmaceuticals (ASX:NSB) began the transfer of its patented manufacturing process for its mesenchymal stromal cells from cell and tissue therapy at the Royal Perth Hospital in Western Australia to Q-Gen Cell Therapeutics (Q-Gen) of QIMR Berghofer Medical Research Institute in Brisbane, Queensland, according to a Thursday Australian bourse filing.

Q-Gen holds a Therapeutic Goods Administration license for cell therapy manufacture, and the commencement of the technology transfer to Q-Gen is an important milestone for NeuroScientific to establish its cell manufacturing.

NeuroScientific's unit, Isopogen Australia Opco, previously signed a manufacturing contract with QIMR Berghofer, under which Q-Gen would undertake manufacturing process development, scale-up, and clinical grade manufacture of the firm's proprietary StemSmart platform technology.

Its shares rose 4% in recent trade.